Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 20, 2026

Arteris Technology Adopted by Li Auto for Intelligent Vehicles

View original at globenewswire.com
Arteris Technology Adopted by Li Auto for Intelligent Vehicles CAMPBELL, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Li Auto's autonomous driving SoC provides the L9 Livis SUV with 2,560 TOPS of computing power to effectively perform AI computational tasks for autonomous vehicles.

    60% confidence
  • Li Auto started volume production in November 2019 and its current model lineup includes a high-tech flagship family MPV, four Li L series extended-range electric SUVs, and two Li i series battery electric SUVs.

    60% confidence
  • Arteris technology is supporting AI compute data movement and integration automation for Li Auto's current and future smart vehicles.

    60% confidence
  • Using Arteris FlexNoC 5 physical awareness capabilities, Li Auto quickly converged on optimal SoC architecture in the 5nm process node, reducing design risk and improving system-level efficiency.

    60% confidence
  • Li Auto is committed to delivering intelligent vehicles that seamlessly integrate advanced AI, safety, and user experience, and Arteris plays a key role in that strategy. Li Auto chose Arteris to meet high functional, performance, and safety requirements for autonomous driving chips and to ensure a great user experience in smart vehicles.

    60% confidence
  • Automotive innovation is being driven by a fundamental shift toward centralized compute and AI-defined functionality. Silicon data movement is a critical factor in meeting the performance, power, safety and security requirements of today's physical AI systems.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com